Literature DB >> 7723396

The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia.

J Anastasi1, J Feng, M M Le Beau, R A Larson, J D Rowley, J W Vardiman.   

Abstract

Chronic myelogenous leukemia (CML) is a stem cell disorder which progresses from a chronic phase (CP) to an accelerated phase (AP), and/or a blast phase (BP) of myeloid (M) or lymphoid (L) phenotype. This progression is frequently preceded or accompanied by recurring secondary chromosomal abnormalities which are believed to play a role in the transformation. In order to investigate the relationship between the secondary change and the development of BP, we undertook a study using fluorescence in situ hybridization to determine in which cells the secondary abnormalities were present. We observed that in one case of L-BP, the secondary change (trisomy 8) appeared to be in a subclone that was different from the blast cells, as it was absent from the lymphoblasts but present in differentiating erythroid, monocytic and granulocytic cells. In two cases, the secondary change (trisomy 8, extra Ph) probably occurred prior to an acute transforming event as it was present in CP or AP predominantly in differentiated granulocytic or monocytic cells. In one case of M-BP, the secondary change (trisomy 8) probably occurred after the acute transformation, as it appeared in only a subset of the blasts. Lastly, in four cases of L-BP, the secondary change (monosomy 7, extra Ph or hyperdiploidy) was closely associated with the BP as it was present in all of the blasts. The findings indicate that some secondary abnormalities may be directly related to the development of BP and may provide clues to the identity of genes responsible for the acute phase transition. Other abnormalities occurring before, or after the acute transformation or in a different subclone from the acute phase blasts, may be more important for denoting genomic instability than for helping to understand the mechanism of blast transformation.

Entities:  

Mesh:

Year:  1995        PMID: 7723396

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

Authors:  Alireza Salem; Sanam Loghavi; Guilin Tang; Yang O Huh; Elias J Jabbour; Hagop Kantarjian; Wei Wang; Shimin Hu; Rajyalakshmi Luthra; L Jeffrey Medeiros; Joseph D Khoury
Journal:  Am J Hematol       Date:  2017-04-06       Impact factor: 10.047

Review 2.  Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis.

Authors:  Soranobu Ninomiya; Nobuhiro Kanemura; Hisashi Tsurumi; Senji Kasahara; Takeshi Hara; Toshiki Yamada; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2011-04-27       Impact factor: 2.490

3.  Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.

Authors:  Dushyant Verma; Hagop Kantarjian; Jianqin Shan; Susan O'Brien; Zeev Estrov; Guillermo Garcia-Manero; Charles Koller; Gautam Borthakur; Jorge Cortes
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

4.  Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case.

Authors:  Walid Al-Achkar; Faten Moassass; Adnan Ikhtiar; Thomas Liehr; Moneeb Abdullah Kassem Othman; Abdulsamad Wafa
Journal:  Mol Cytogenet       Date:  2014-11-29       Impact factor: 2.009

5.  High-risk additional chromosomal abnormalities at low blast counts herald death by CML.

Authors:  Rüdiger Hehlmann; Astghik Voskanyan; Michael Lauseker; Markus Pfirrmann; Lida Kalmanti; Sebastien Rinaldetti; Katharina Kohlbrenner; Claudia Haferlach; Brigitte Schlegelberger; Alice Fabarius; Wolfgang Seifarth; Birgit Spieß; Patrick Wuchter; Stefan Krause; Hans-Jochem Kolb; Andreas Neubauer; Dieter K Hossfeld; Christoph Nerl; Alois Gratwohl; Gabriela M Baerlocher; Andreas Burchert; Tim H Brümmendorf; Jörg Hasford; Andreas Hochhaus; Susanne Saußele; Michele Baccarani
Journal:  Leukemia       Date:  2020-05-07       Impact factor: 11.528

6.  Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient.

Authors:  Walid Al-Achkar; Abdulsamad Wafa; Faten Moassass; Elisabeth Klein; Thomas Liehr
Journal:  Oncol Lett       Date:  2013-03-05       Impact factor: 2.967

7.  The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.

Authors:  A M Crisan; D Coriu; C Arion; A Colita; C Jardan
Journal:  J Med Life       Date:  2015 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.